DDX3-IN-2|cas:1919828-81-1|西域试剂

DDX3-IN-2,99.36%

产品编号：Bellancom-121969| CAS NO：1919828-81-1| 分子式：C₂₀H₂₃N₅O| 分子量：349.43

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-121969	￥1800.00	杭州北京（现货）
Bellancom-121969	￥3000.00	杭州北京（现货）
Bellancom-121969	￥5900.00	杭州北京（现货）
Bellancom-121969	￥9500.00	杭州北京（现货）
Bellancom-121969	￥15000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DDX3-IN-2

产品介绍

DDX3-IN-2 是一种活性 DEADbox polypeptide 3 (DDX3) 抑制剂，其 IC₅₀ 值 0.3 μM。DDX3-IN-2 表现出广谱的抗病毒活性。DDX3-IN-2 有克服 HIV 耐药的潜力。

生物活性

DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC₅₀ value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance.

体外研究

DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg.
DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats
Dosage:	Tail vein injection
Administration:	20 mg/kg
Result:	Possessed excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg.

Animal Model:	Rats
Dosage:	I.v. bolus injection (Pharmacokinetic Analysis)
Administration:	10 mg/kg; 0~25 hours
Result:	Rapidly eliminated the half-life elimination and the plasmatic clearance values.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats
Dosage:	Tail vein injection
Administration:	20 mg/kg
Result:	Possessed excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg.

Animal Model:	Rats
Dosage:	I.v. bolus injection (Pharmacokinetic Analysis)
Administration:	10 mg/kg; 0~25 hours
Result:	Rapidly eliminated the half-life elimination and the plasmatic clearance values.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (286.18 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8618 mL	14.3090 mL	28.6180 mL
5 mM	0.5724 mL	2.8618 mL	5.7236 mL
10 mM	0.2862 mL	1.4309 mL	2.8618 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.15 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。